← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Humana grew revenue, but the cash-flow decline and Medicare quality pressure make the year harder than the top line looks.
The read at a glance✓ Audited against SEC data
- Growth — +10.1% revenue to $129.66BOK
- Profitability — Net income -1.6% to $1.19BNote
- Cash quality — Free cash flow -84.3% to $0.38BWatch
- Margins — FCF margin -174 bps; net margin -10 bpsWatch
- Balance sheet — Debt +11.0%; equity +7.8%Note
- Insiders — 1 open-market buy / 0 sellsOK
Business
Humana is a health insurer and care-delivery company built around Insurance and CenterWell. Insurance includes Medicare benefits, state-based contracts, and related products; CenterWell includes pharmacy, primary care, and home-health services.
Where the revenue comes from
Fiscal 2025, as HUMANA INC reports it. History and quarterly detail are in the app.
Leadership changes
From HUMANA INC's own filings, the day they're filed.
- Medicare Advantage · President · appointmenteff. 2025-12-16
- Bruce D. Broussard · Chief Executive Officer · departureeff. 2023-10-11
- John Barger · President · appointment
Latest filings
- 8-K · Company announcement2026-09-01
- 8-K · Company announcement2026-07-29
- 10-Q · Quarterly report2026-07-29
- 8-K · Company announcement2026-07-29
- 8-K · Company announcement2026-06-01
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about HUMANA INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.